FOLD - Amicus Therapeutics, Inc.
14.45 -0.19 (-1.30%)
Pre-Market: 8:29AM EDT
| Previous Close | 14.77 |
| Open | 14.73 |
| Bid | 14.40 x 300 |
| Ask | 15.08 x 200 |
| Day's Range | 14.38 - 15.06 |
| 52 Week Range | 6.41 - 17.40 |
| Volume | 1,536,735 |
| Avg. Volume | 3,139,316 |
| Market Cap | 2.752B |
| Beta | 1.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire•3 days ago
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day
CRANBURY, N.J., April 17, 2018-- Amicus Therapeutics is participating in several activities in April to honor Fabry Disease Awareness Month and International Pompe Day. The Fabry community has designated ...
- GlobeNewswire•4 days ago
Report: Developing Opportunities within Amicus Therapeutics, Rite Aid, Navient, ProPetro Holding, Pfizer, and Sysco — Future Expectations, Projections Moving into 2018
NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•28 days ago
Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan
CRANBURY, N.J., March 22, 2018-- Amicus Therapeutics announced today that Japan's Ministry of Health, Labour and Welfare has approved the oral small molecule pharmacological chaperone Galafold ® capsules ...
- GlobeNewswire•last month
Research Report Identifies Rayonier, Gannett Co., CBIZ, Amicus Therapeutics, Iamgold, and Urban Outfitters with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•2 months ago
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2018
CRANBURY, N.J., March 05, 2018-- Amicus Therapeutics today announced upcoming presentations at two investor conferences in March.. John F. Crowley, Chairman and Chief Executive Officer, will present a ...
- ACCESSWIRE•2 months ago
Today’s Research Reports on Trending Tickers: Gilead Sciences and Amicus Therapeutics
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / U.S. markets closed lower Wednesday to end February in the red, with the Dow Jones and S&P 500 breaking its longest monthly gain streak since 1959. The Dow Jones ...
- GlobeNewswire•2 months ago
Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates
Galafold Expansion Continues with 360+ Fabry Patients Treated Today- on Track to Achieve FY18 Revenue Guidance of $75 M- $85 M. Significant Progress Across Pompe Clinical, Regulatory and Manufacturing ...
- ACCESSWIRE•2 months ago
Amicus Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Amicus Therapeutics, Inc. (NASDAQ: FOLD ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 28, 2018, at 8:30 AM ...
- GlobeNewswire•2 months ago
Amicus Therapeutics Launches Healing Beyond Disease™ Initiatives to Change People’s Lives Living with Rare Diseases
CRANBURY, N.J., Feb. 27, 2018-- Amicus Therapeutics is honoring Rare Disease Day this week with the launch of Healing Beyond Disease™, a global, Amicus employee-driven initiative inspired by people living ...
- GlobeNewswire•2 months ago
Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
CRANBURY, N.J., Feb. 21, 2018-- Amicus Therapeutics today announced the closing of its previously announced offering of common stock. The Company issued a total of 19,354,839 shares in the offering at ...
- GlobeNewswire•2 months ago
Amicus Therapeutics to Announce Full-Year 2017 Financial Results on February 28, 2018
CRANBURY, N.J., Feb. 21, 2018-- Amicus Therapeutics today announced a conference call and live audio webcast on Wednesday, February 28, 2018 at 8:30 a.m. ET to discuss financial results for the full year ...
- GlobeNewswire•2 months ago
Amicus Therapeutics Prices Underwritten Offering of Common Stock
CRANBURY, N.J., Feb. 15, 2018-- Amicus Therapeutics today announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share. The gross proceeds from the offering ...
- GlobeNewswire•2 months ago
Amicus Therapeutics Announces Public Offering of Common Stock
CRANBURY, N.J., Feb. 14, 2018-- Amicus Therapeutics today announced it has commenced a $250 million underwritten public offering of its common stock. Morgan Securities LLC and Goldman Sachs & Co. LLC are ...
- ACCESSWIRE•2 months ago
Blog Exposure - FDA Accepts Amicus Therapeutics’ NDA for Migalastat for Treatment of Fabry Disease
Stock Monitor: Immunomedics Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 14, 2018 / Active-Investors.com has just released a free research report on Amicus Therapeutics, Inc. (NASDAQ: FOLD ...
- GlobeNewswire•2 months ago
Amicus Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference
CRANBURY, N.J., Feb. 13, 2018-- Amicus Therapeutics today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the LEERINK Partners ...
- GlobeNewswire•2 months ago
U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
CRANBURY, N.J., Feb. 12, 2018-- Amicus Therapeutics today announced that the U.S. Food and Drug Administration has accepted the New Drug Application for filing under priority review for the oral precision ...
- GlobeNewswire•2 months ago
Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium™
Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Out to Month 12. Very Low Rate ( Maintained After 550+ Infusions. CRANBURY, N.J. and SAN DIEGO, Feb. 07, ...
- ACCESSWIRE•3 months ago
Today’s Research Reports on Trending Tickers: Geron Corporation and Amicus Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / January 30, 2018 / U.S. markets posted their worst day of 2018 on Monday as the yield on the benchmark 10-year Treasury note traded at the highest level since April 2014. The ...
- GlobeNewswire•3 months ago
Canadian Drug Expert Committee Grants Positive Recommendation for Reimbursement of Galafold™ (migalastat) for Fabry Disease in Canada
CRANBURY, N.J., Jan. 29, 2018-- Amicus Therapeutics announced that the Common Drug Review has posted the Canadian Drug Expert Committee’ s positive recommendation of Galafold™ for listing with provincial ...
- GlobeNewswire•3 months ago
Amicus Therapeutics Announces Presentations and Posters at 14th Annual WORLDSymposium™ 2018
CRANBURY, N.J., Jan. 22, 2018-- Amicus Therapeutics, today announced that two oral presentations and seven posters highlighting its development programs for Lysosomal Storage Disorders will be included ...
- ACCESSWIRE•3 months ago
Today’s Research Reports on Trending Tickers: Amicus Therapeutics, Inc. and Synergy Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / January 8, 2018 / U.S. markets continued their impressive run on Friday to close the week with impressive gains. Both the Dow and the Nasdaq have posted its largest four-day ...